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Abstract
Background: Previous studies demonstrated both pre-clinically and clinically the feasibility of magnetic resonance-
guided high-intensity focused ultrasound (MR-HIFU) ablations in the liver. To overcome the associated problem of
respiratory motion of the ablation area, general anesthesia (GA) and mechanical ventilation was used in conjunction
with either respiratory-gated energy delivery or energy delivery during induced apnea. However, clinical procedures
requiring GA are generally associated with increased mortality, morbidity, and complication rate compared to
procedural sedation and analgesia (PSA). Furthermore, PSA is associated with faster recovery and an increased
eligibility for non- and mini-invasive interventions.
Methods: In this study, we investigate both in an animal model and on a small patient group the kinetics of the
diaphragm during free-breathing, when a tailored remifentanil/propofol-based PSA protocol inducing partial
respiratory depression is used. Subsequently, we demonstrate in an animal study the compatibility of the resulting
respiratory pattern of the PSA protocol with a gated HIFU ablation in the liver by direct comparison with gated
ablations conducted under GA. Wilcoxon signed-rank tests were performed for statistical analysis of non-perfused
and necrosed tissue volumes. Duty cycles (ratio or percentage of the breathing cycle with the diaphragm in its
resting position, such that acoustic energy delivery with MR-HIFU was allowed) were statistically compared for both
GA and PSA using student’s t tests.
Results: In both animal and human experiments, the breathing frequency was decreased below 9/min, while
maintaining stable vital functions. Furthermore an end-exhalation resting phase was induced by this PSA protocol
during which the diaphragm is virtually immobile. Median non-perfused volumes, non-viable volumes based on
NADH staining, and duty cycles were larger under PSA than under GA or equal.
Conclusions: We conclude that MR-HIFU ablations of the liver under PSA are feasible and potentially increase the
non-invasive nature of this type of intervention.
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Background
High-intensity focused ultrasound (HIFU) ablation of
liver tumors was one of the first HIFU applications
under investigation [1]; even after several decades of
methodological refinement, HIFU ablation in the liver
faces still several challenges, which hamper widespread
clinical adoption and remains a topic of research [2–6].
The thoracic cage and the lung partially obstruct acous-
tic access to the tumor, thereby limiting the locations
directly accessible with extracorporeal HIFU-transducers
[7, 8]. Furthermore, the high perfusion of the liver re-
quires high acoustic intensities in the focus during a
sonication for an efficient energy deposition to overcome
this so-called heat-sink effect [9, 10], which in-turn
limits the achievable ablation volume per sonication. Fi-
nally, respiratory motion causes a continuous displace-
ment of the target lesion.
Two techniques for guidance of HIFU-treatments are
widely used, which are ultrasound [11, 12] and magnetic
resonance imaging. With respect to the previously men-
tioned challenges in the liver, both methods have their
specific advantages and disadvantages. In this paper, we
focus on magnetic resonance guided HIFU (MR-HIFU).
MR-HIFU applies high-intensity sound waves transcuta-
neous into the body for thermal tissue ablation and is a
fully non-invasive therapeutic modality. The excellent
anatomical contrast of the associated MRI is thereby
used for localization and delineation of the lesion and
the possibility of accurate real-time temperature moni-
toring allows guidance during tissue ablation. As a con-
sequence, MR-HIFU is meanwhile a well-established
treatment option for uterine fibroids and is currently
investigated for, e.g., bone tumors [13], breast cancer
[14, 15], prostate cancer [16], and liver cancer [10, 17].
In MR-guided liver treatments an additional challenge
is the continuous movement of the target due to the re-
spiratory cycle that requires motion compensation strat-
egies for both MR thermometry and acoustic energy
deposition. For the latter, several strategies have been
suggested to address respiratory induced liver motion,
ranging from induced apnea, over gated approaches, to
dynamic beam-steering [3, 18, 19].
Similarly, real-time PRF-thermometry (proton reson-
ance frequency-thermometry) for therapy guidance has
been adapted to respiratory motion with multi-baseline
phase corrections, referenceless PRF-thermometry ap-
proaches, hybrid correction schemes, and gated MR-
thermometry [20–23].
Although MRI guidance has the advantage of real-time
temperature mapping, to date, very few studies have
combined MR guidance with the abovementioned HIFU
strategies on clinical equipment into a clinically feasible
treatment protocol [24]. Animal studies focused mainly
on technical developments, while clinical studies mostly
used ultrasound guidance, which currently lacks real-
time temperature monitoring. The few liver tumor
treatments with MR-HIFU that have been reported all
used controlled apnea to mitigate respiratory problems
[24–26]. More recently, our group studied MR-HIFU of
the liver in a porcine model and demonstrated the feasi-
bility of creating a confluent ablation volume using
clinical HIFU equipment, which is modified to allow re-
spiratory gating [10]. The ablations were performed
under general anesthesia (GA) using mechanical ventila-
tion in combination with an MR pencil beam navigator
on the diaphragm to allow for respiratory-triggered ac-
quisition of the anatomical scans and thermometry and
most importantly for respiratory-gated acoustic energy
deposition. The latter assures that no energy is deposited
outside the target region if the diaphragm—and thereby
the liver—is displaced from its resting position due to
respiration. By using mechanical ventilation, the fre-
quency of inhalation and exhalation and the duration of
the resting phase can be chosen within the boundary of
physiologically safe parameters.
Alternatively, another particular form of ventilation
that can be used under general anesthesia is high fre-
quency jet ventilation, which is able to deliver jets at
rates of 60–100 min−1 [27]. The advantage of this tech-
nique is the small tidal volume leading to little respira-
tory motion (3 mm) [28, 29]. However, there are several
disadvantages to this technique, such as its invasive na-
ture due to the need for total muscle relaxation and the
insertion of an endotracheal tube; carbon dioxide moni-
toring is difficult and requires, e.g., cessation of respir-
ation for side-stream sampling or gas sampling from an
arterial line; emergent re-intubation with a common
endotracheal tube was needed in 10 % of all study sub-
jects as laryngeal mask ventilation was insufficient and
oxygen saturation dropped below 70 %, and several risks
are present while using this technique such as regurgita-
tion (gastroesophageal reflux), severe bleeding, and pul-
monary barotrauma [27, 30]. Concerns mentioned by
the authors of two recent papers include inability to
treat tumors in the liver dome area as they may be
obscured by the lung, the non-existence of an MR-
compatible device to induce high frequency jet ventila-
tion, and the requirement of a specialized anesthetic
team [31–33].
In summary, all aforementioned approaches, including
induced apnea, mechanical ventilation with gating strat-
egies, or high-frequency jet-ventilation require essen-
tially GA over the entire duration of the intervention.
Unfortunately, GA is frequently associated with mortal-
ity, morbidity, and complications [34], in particular with
elderly and more fragile patients in advanced stage of
disease [35, 36]. Of all deaths, 46.6 % were associated
with an anesthesia overdose, 42.5 % with adverse effects,
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and 3.6 % with pregnancy/obstetric care. Known compli-
cations are impaired cardiovascular function, postopera-
tive cognitive dysfunction in the elderly, cardiac arrest
(sometimes with fatal outcome), hypotension and brady-
cardia, peripheral neuropathies, skin burns, dental dam-
age, acute myocardial infarction, and irreversible
cerebral damage [37–40]. An increase in death rates was
observed in patients with relevant comorbidities, which
is not an unlikely case in HIFU patients, and according to
German data, the proportion of patients older than 65
who had to undergo surgery rose from 38.8 % (n = 4.7 mil-
lion) to 40.9 % (n = 5.9 million) from 2005 to 2009 [36]. In
other words, anesthesia-associated mortality has risen
again in purely numerical terms due to an increase in the
proportion of elderly—often multimorbid—undergoing
surgery. Elderly people with comorbidities are one of the
target groups of MR-HIFU due to its non-invasive nature.
Since MR-HIFU interventions are generally lengthy (>2–
3 h), the need for GA over these long durations reduces
the non-invasive aspect of MR-HIFU, which represents
one of its major advantages.
A potential way to overcome this shortcoming is the
use of procedural sedation and analgesia (PSA) [41] in-
stead of GA. In comparison, PSA is known to cause
fewer complications and has a better compatibility with
other flanking oncological interventions, such as chemo-
therapy or surgery. Respiratory arrest and airway ob-
struction should be carefully checked for throughout the
procedure as these are two possible complications of
PSA, although not commonly encountered. PSA ususally
has minimal influence on cardiovascular function [42].
Points of comparison where PSA shows more favor-
able characteristics than GA are, e.g., less requirement
for intervention of the airways during a procedure, the
ability to maintain spontaneous ventilation during a
treatment, and the ability to maintain good cardiovascu-
lar function [41]. Furthermore, recovery is faster after
PSA leading to the possibility of ambulatory treatment.
Therefore, the burden and risks of PSA for patients is
much less than for GA. Moreover, patients with severe
disease may not be eligible for, e.g., MR-HIFU performed
under GA but can be treated under PSA.
On the other hand, the principal shortcoming of PSA
as a replacement for GA in combination with mechan-
ical ventilation is that the patient is essentially free-
breathing during the entire duration of the intervention.
While the respiratory breathing pattern under mechan-
ical ventilation displays in general a brisk and short
inhalation-exhalation event, followed by a lengthy period
of complete standstill of the diaphragm, free-breathing
results in much longer inhalation-exhalation events, with
a smoothed out motion pattern of the diaphragm, which
is also frequently subject to drifts and a-periodic events
[43]. As a consequence, the achievable duty cycle for
gated HIFU energy delivery under free-breathing is sub-
stantially more unfavorable compared to mechanical
ventilation.
A potential way to overcome this disadvantage is to
manipulate the kinetics of the diaphragm during free-
breathing by the appropriate medication. One of the old-
est known families of drugs introducing a partial respira-
tory depression are opioids. However, there are several
types of opioid receptors in the human body, for which
each type of opioid displays different affinities and inter-
actions, which in turn leads to unique modifications of
the respiratory cycle [44, 45]. Two of the most fre-
quently used opioids in clinical anesthesia are fentanyl
and its N-4 thienyl derivative, sufentanil, which are con-
sequently well understood with respect to their effect on
the respiratory system [46].
In the scope of this study, we investigate in a porcine
model if a remifentanil-based PSA protocol leads to a
slow and regular respiratory pattern, which allows an ef-
fective and reproducible respiratory-gated MR-HIFU en-
ergy deposition in the liver. Since in addition to the
required partial respiratory depression a sedative effect
is highly desirable, remifentanil is thereby combined
with the hypnotic/amnestic agent propofol, which repre-
sents one of the most wide-spread used drugs for the in-
duction and maintenance of general anesthesia or
sedation [47]. The study compares directly MR-HIFU
ablations under PSA and under GA with respect to
achieved duty cycle, achieved non-perfused volume and
the resulting non-viable tissue volume assessed by
histopathology.
Subsequently, the proposed PSA protocol was evalu-
ated in sedated human patients in order to evaluate if
the conclusions gained on the animal model with respect
to the achieved respiratory depression and the stability
of the induced respiratory pattern are transferable into a
feasible clinical protocol. For this, two uterine fibroid
MR-HIFU treatments and one bone metastasis MR-
HIFU treatment were conducted with the proposed PSA




The experimental protocol was designed with a clinical
MR-HIFU ablation of a small (1–2 cm) malignant liver
tumor in mind for which a slow breathing cycle with a
long resting phase is required. For this reason, the em-
phasis was placed on comparing the ablation of the total
target volume under PSA with treating a similar target
volume under comparable circumstances under GA. In
short, two target volumes were planned in the liver at
similar shot depths with similar near field tissues and
with similar distances to large hepatic vessels. The first
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target volume was ablated under PSA. This part of the
experiment investigated if a remifentanil based PSA
protocol can induce a partial respiratory depression,
which leads to a slow and regular breathing pattern with
long exhalation phases, while maintaining stable and safe
vital functions under free-breathing conditions. Subse-
quently, an adjacent second target volume was ablated
under GA with mechanical ventilation. In this part of
the experiment, a strong synthetic opiate (sufentanil)
induces a complete respiratory depression and the re-
spiratory motion cycle is entirely determined by the pa-
rameters of the mechanical ventilation system. For both
approaches, a pencil beam navigator on the diaphragm
was used for a respiratory-triggered acquisition of the
initial anatomical scans used for planning, the PRF-
thermometry used for the interventional guidance dur-
ing the energy deposition and for the acoustic energy de-
position itself. Analyses included an evaluation of post-
procedural contrast enhanced (CE) T1-weighted images,
duty cycle calculations based on the navigator data, MR
thermometry data, and histological samples.
Animal model
The study was approved by our institution’s animal
experimental committee (“Dier experiment commissie
Utrecht”, reference number 2014.III.01.013, protocol
number 104777-1). A porcine model was chosen
because of the similarity between the porcine and the
human liver in terms of size and perfusion. Furthermore,
dosages of remifentanil and propofol reported in litera-
ture are comparable for weight-matched pigs and human
patients [48, 49]. Healthy female Dalland land pigs of
55–70 kg (– = 8) were placed in prone position on the
MR-HIFU system after shaving the skin and application
of ultrasound gel.
Procedural sedation and analgesia and general anesthesia
First, PSA was induced using intravenous (i.v.) infusion
of propofol (4.5–6 mg/kg/h) and remifentanil (4.8–
5.8 μg/kg/h) by two experienced biotechnicians/vetere-
narians. Remifentanil has a depressant effect on respir-
ation and a short plasma half-life of <10 min [50]. The
depressant effect on respiration allows for a high duty
cycle of the HIFU ablation. The short plasma life is fa-
vorable for adjusting the breathing frequency and de-
creases the risk of, e.g., apnea requiring intervention.
Volumetric sonications were performed (seven to nine
sonications per animal) under PSA. MRI and acoustic
energy delivery were respiratory gated using a pencil
beam navigator similar to Wijlemans et al. [10]. Subse-
quently, GA was induced using midazolam (1 mg/kg/h),
cisatracurium (0.09 mg/kg/h), and sufentanil (11.3 μg/
kg/h). The animal was mechanically ventilated to ensure
optimal control over the respiration (Smiths Medical
Pneumac paraPAC, Kent, UK). The respiratory fre-
quency was set to 13/min, resulting in a respiratory cycle
of 4.5 s with an exhalation phase of 3 s in which the dia-
phragm is at rest (±1.5 mm). The protocol was repeated
after 3 min of cool down to prevent undesired accumu-
lative thermal damage in the near-field. The animal’s
blood pressure, exhaled CO2 concentration, and heart
frequency were monitored during the entire experiment.
MR-HIFU system
All experiments were performed on a clinical Sonalleve
MR-HIFU therapy system (Philips Healthcare, Vantaa,
Finland) integrated with a 1.5T Achieva MRI (Philips
Healthcare, Best, The Netherlands) [51]. The 256-
element HIFU transducer allowed for volumetric abla-
tion using electronic beam steering [52]. An acoustically
transparent cooling cushion was placed between the ani-
mal and the acoustic window of the HIFU table to cool
the skin and minimize the risk of skin burns. Cold water
(15 °C) was circulated through the cooling cushion. To
prevent systemic hypothermia of the animal, a heating
pad with circulating warm water (35 °C) was placed on
the back of the animal.
All MR sequences, including planning, thermometry
scans, and follow-up contrast-enhanced imaging, were ei-
ther obtained with respiratory gating or respiratory trig-
gering using 2D navigator pulses (in the scope of this
manuscript referred to as pencil beam navigators [53]).
The pencil beam navigator was placed on the diaphragm
adjacent to the ablation area to ensure spatial consistency
between all acquired images [53]. Similarly, the energy de-
livery was respiratory-gated in the following manner: for
the end-expiration phase, a gating window was defined
with a width of typically 3 mm. The CDAS acquisition sys-
tem of the MRI was modified to provide a transistor-
transistor logic (TTL) signal on a dedicated hardware port,
which indicates the presence of the diaphragm in the
gating window. Based on this output, an Atmel microcon-
troller (ATmega32u4, Atmel Corporation, San Jose,
California) based interface board generates a 20-Hz trigger
signal for the HIFU generator system where a TTL-
triggered sonication protocol was executed. Every TTL-
pulse triggered a pulse train of 50 ms in length. Arrival of
the pulses was logged by the HIFU software and was avail-
able for analysis post-treatment.
MR imaging
Pre-procedural MR imaging included at least one T2-
weighted planning scan (3D TSE, TR 1440 ms, TE
130 ms, matrix 208 × 180, FOV 250 × 250 × 200 mm, re-
constructed voxel size 0.49 × 0.49 × 3 mm3, turbo factor
83). Proton resonance frequency shift (PRFS) thermom-
etry was used for real-time temperature mapping in
three planes (GE-EPI, TR 100 ms, TE 15 ms, flip angle
van Breugel et al. Journal of Therapeutic Ultrasound  (2016) 4:19 Page 4 of 12
20°, matrix 160 × 160, FOV 400 × 400 mm, voxel size
2.5 × 2.5 × 5 mm3, EPI factor 17). One coronal MR slice
was centered on the focal point, perpendicular to the
symmetry axis of the HIFU beam; one sagittal slice was
centered on the focal point, parallel to the beam axis;
and one coronal slice was placed in the abdominal
muscle for near field monitoring. The pencil beam navi-
gator triggered the acquisition of all three slices at the
beginning of the resting phase of the diaphragm. Post-
procedural imaging included at least a dynamic contrast-
enhanced T1-weighted scan to determine the extent of
the non-perfused volume (NPV) (3D gradient echo
(THRIVE) TR 5.4 ms, TE 2.6 ms, flip angle 10°, matrix
168 × 132, FOV 80 × 250 × 250 mm3, voxel size 0.49 ×
0.49 × 3 mm3, slice gap −1.5 mm, turbo factor 44, SPIR).
Ablation procedure
Two target volumes were defined within the liver: one
for the ablation under sedation and one as control under
general anesthesia. The two chosen parts of the liver
were unobstructed by the ribs (inferior to the sternum
to avoid excessive heating of the thoracic cage), similar
in depth, and similar in distance to large hepatic vessels
(Fig. 1). The overall ablation volume was subdivided in
small volumetric treatment cells (4 × 4 × 10 mm3, 7–10
sonications per target volume), which were sequentially
ablated with high acoustic power (450 W acoustic power,
10–25 s per sonication). Acoustic energy delivery was re-
stricted to the resting position of the diaphragm (2–3-
mm gating window), while the PRFS thermometry was
triggered by the entry of the resting phase. The reference
temperature for PRFS thermometry was set to 37 °C.
The operator was responsible for aborting the sonication
manually when a temperature over 60 °C was observed
in the target area of one treatment cell for at least two
subsequent temperature images (>6 s). A cool down
phase of at least 3 min was allowed between sonications
to limit accumulation of heat in the near field.
A post-treatment contrast-enhanced (Gadovist, Bayer,
Leverkusen, Germany, 1 mmol/kg) dynamic scan was
performed to determine the non-perfused volume
(NPV) of both target volumes. After the experiment, the
animals were euthanized using an overdose of sodium
pentobarbital.
Histology
The liver was resected on the day of the animal experi-
ment and within an hour after termination of the animal.
The coagulated tissue volume, including a margin of
healthy liver tissue, was excised and frozen in liquid nitro-
gen. Frozen samples were prepared for cryosectioning and
sliced in 4-μm thick coronal slices each 1000 μm. Slices
Fig. 1 a A typical example of shot planning of two clusters of seven treatment cells sonicated under general anesthesia (GA) and procedural
sedation and analgesia (PSA) in the liver (L). GB gall bladder. b A typical example of heating in the focal point under GA in the sagittal plane.,
whereby the color scale ranges from 43 °C (blue) to 70 °C (red). c A typical example of heating under PSA in the sagittal plane using the same
color bar as b. d Example of nicotinamide adenine dinucleotide (NADH) staining of a lesion ablated under general anesthesia or under
procedural sedation and analgesia e. Clearly distinguishable regions containing non-viable cells are recognized by its lack of color, while viable
cells turn blue after staining
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were stained with hematoxylin and eosin (HE) for general
histological assessment and with nicotinamide adenine di-
nucleotide diaphorase (NADH) histochemistry for cell via-
bility evaluation.
Patient experiments
Three clinical MR-HIFU treatments of human pa-
tients were performed under procedural sedation and
analgesia satisfying the required standards and in con-
formity with regulatory requirements. Two of these
interventions were uterine fibroid ablations, one a
bone-cancer palliation with HIFU. The conventionally
used PSA protocol for these types of intervention at
our institution is a combination of ketamine and pro-
pofol to induce analgesia and sedation, respectively.
Ketamine does not induce respiratory depression,
which is for both types of therapy also not required.
In the scope of the presented experiments here, the
ketamine was replaced by remifentanil.
The first patient was a 57-year-old woman treated for
a uterine fibroid. For the induction of the sedation, the
following strategy was applied: the remifentanil was kept
at a constant dosage, while the propofol dosage was
slowly increased to lower the breathing frequency to 5/
min. Final dosages for propofol and remifentanil were
1.4 mg/kg/h and 2.5 μg/kg/h, respectively. This stable
breathing pattern was reached after <2 h.
The second patient was a 72-year-old woman with
bone metastases of which one was located in the
shoulder. Here, the strategy was to start with a higher
dosage of remifentanil. However, the remifentanil dos-
age was slowly decreased during the treatment, while
the propofol dose was slowly increased to induce a
deeper state of sleep. A stable, low frequency (5/min)
breathing pattern was reached with 1.6 mg/kg/h
propofol and 0.3 μg/kg/h remifentanil in a little under
an hour.
The third patient was 41 years old and treated for a
uterine fibroid. The dosage of remifentanil was kept
constant at 4.2 μg/kg/h and the dosage of propofol
was adjusted to the patient’s state of sedation during
the treatment and was finally 2.2 mg/kg/h. After the
treatment was completed, an additional MR scan
(spoiled gradient echo with echo planar imaging, EPI-
factor 25, TE 15 ms, TR 39 ms, flip angle 20°, acqui-
sition matrix 120 × 98, pixel size 2.34 × 2.34 mm, slice
thickness 7 mm) was performed to visualize the dis-
placement of the diaphragm due to respiration.
One hundred percent oxygen was continuously of-
fered using a nasal prong in all three patients. End
tidal carbon dioxide (ETCO2) was measured using
capnography. Furthermore, breathing frequency, blood
pressure values, and heart rate were monitored.
Data analysis
An image intensity-based semi-automatic segmentation
algorithm (MeVisLab, MeVis Medical Solutions AG,
Bremen, Germany) [4] was used to determine the NPVs
on CE-T1w imaging to compare the lesions ablated
under PSA and GA. An NPV per sonication was calcu-
lated by dividing the total NPV of each lesion by the
number of treatment cells composing that particular le-
sion. Wilcoxon signed-rank test was used to test for
equality in NPV.
Areas of non-viable tissue were calculated by measur-
ing the width and the length of the region showing less
or no staining NADH histology sections and assuming
an ellipsoidal shape. The distance between two subse-
quent sections was 1000 μm. A total non-viable lesion
volume was calculated by summing the volumes of the
individual sections. Wilcoxon signed rank test was used
to check for equality in necrosed tissue volume.
Duty cycles (ratio or percentage of the breathing cycle
with the diaphragm in its resting position, such that
acoustic energy delivery with MR-HIFU was allowed)
were calculated based on the logged TTL-pulses arriving
at the HIFU generator system as a result of the previ-




where npulse is the number of pulses that trigger energy
delivery, T the length of a single pulse-train (=50 ms),
tfirst (ms), and tlast (ms) are the arrival time of the first
and last pulse triggering energy delivery.
Both the duration of the sonication and the duty cycles
during the entire ablation of one target volume were
compared for PSA and GA using the Student’s t test
after verifying normality using P-P plots.
To visualize the breathing pattern in a patient under
sedation a vertical line through the diaphragm on the




A total of 57 sonications were performed under PSA in
eight animals with a median of seven sonications per tar-
get volume (range seven to eight sonications per target
volume). A total of 61 treatment cells were ablated
under GA in the same eight pigs with a median of 7
(range 7–10 treatment cells per target volume). The
non-perfused volume created in one pig could not be
analyzed as sonications overlapped with those of a pre-
ceding experiment. The sonications resulted in a median
NPV of 1.16 mL (IQR 0.70–1.31 mL, range 0.48–
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1.50 ml) for the target volumes ablated under PSA and
0.70 mL (IQR 0.55–0.96 ml, range 0.51–1.29 ml) under
GA (Table 1 and Fig. 2). The average NPV per sonic-
ation was 0.15 mL (range 0.07–0.21 mL/sonication) for
ablations under PSA and 0.10 mL (0.057–0.18 mL/sonic-
ation) under GA. Wilcoxon signed-rank test showed that
the NPV created under PSA and GA is statistically not
different (p = 0.173).
Non-viable tissue volume
Sectioning and NADH staining of the excised liver tis-
sue volumes showed non-viable tissue (recognizable
by its lack of staining), a border zone (recognizable by
its pale blue color, however, not observed in all cases),
and viable tissue, which appears as dark blue due to
the stained samples (Fig. 1). Both the non-viable re-
gion and the border zone were calculated as non-
viable tissue, since it was reported previously that the
necrotic tissue area after MR-HIFU ablation increases
during the first day post treatment and analyses per-
formed in the first few hours lead to an underestima-
tion of the necrotic tissue volume [54–56]. Examples
of sections with clearly distinguishable non-viable and
viable regions obtained under PSA or GA are shown
in Fig. 1.
Lengths and widths were measured and volumes
were calculated assuming an ellipsoidal area and a
slice thickness of 1000 μm. Under PSA, a median
non-viable tissue volume of 0.92 mL (IQR 0.41–
1.37 mL, range 0.25–1.37 mL) was ablated. The me-
dian non-viable tissue volume obtained under GA
was 0.88 mL (IQR 0.70–0.93, range 0.46–1.26 mL).
Per sonication a median non-viable tissue volume of
0.12 mL (range 0.06–0.28 mL/sonication) was ob-
tained under PSA. The median non-viable tissue vol-
ume obtained under GA was 0.13 mL per sonication
(range 0.066–0.18 mL/sonication). Wilcoxon signed-
rank test proved that there was no statistically signifi-
cant difference in necrosed tissue volume between
PSA and GA.
While excising the ablated liver volumes, the near field
and the skin were carefully checked for damage and skin
burns. No abnormalities were observed in the skin, sub-
cutaneous fat layer or abdominal muscle in all cases.
Also Glisson’s capsule of the liver was intact in all eight
pigs, even when the ablation zone extended to the outer
surface of the liver.
Table 1 Overview of the number of sonications performed to
create a lesion per experiment performed either under procedural
sedation and analgesia (PSA) or general anesthesia (GA), of the non-
perfused volume (NPV) obtained from these sonications, the mean
NPV created per sonication, the non-viable volume as observed by
nicotinaminde adenine dinucleotide (NADH) staining for the entire
cluster, and the mean non-viable volume per sonication
Experiment #sonications NPV (mL) NPV/sonication (mL)
PSA GA PSA GA PSA GA
1 7 10 0.70 0.70 0.10 0.070
2 8 9 1.16 0.51 0.15 0.057
3 7 7 1.13 1.29 0.16 0.18
4 7 7 1.50 0.55 0.21 0.079
5 7 7 1.31 0.56 0.19 0.080
6 7 7 – – – –
7 7 7 0.48 0.94 0.069 0.13
8 7 7 1.30 0.96 0.19 0.14
Experiment NADH (mL) NADH/sonication (mL)
PSA GA PSA GA
1 0.89 0.46 0.13 0.046
2 0.95 0.19 0.12 0.021
3 0.13 0.46 0.019 0.066
4 1.01 0.05 0.14 0.0071
5 1.55 0.47 0.22 0.067
6 – – – –
7 0.41 0.74 0.056 0.11
8 0.92 0.89 0.13 0.13
Fig. 2 Ablation volumes per sonication for procedural sedation
and analgesia (PSA) and general anesthesia (GA). NPV ablation
volumes based on the non-perfused volume (NPV) as obtained
from contrast-enhanced MR-scans, NADH non-viable tissue volumes
based on nicotinamide adenine dinucleotide (NADH) staining, TD
ablation volume based on the lethal thermal dose (TD) volume as
calculated by the HIFU software
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Breathing frequency, duty cycle, and the duration of the
sonications
The breathing frequency was fixed at 13/min under gen-
eral anesthesia by using mechanical ventilation. Stable
free breathing patterns were obtained under PSA.
Breathing frequencies under PSA varied between 9 and
15 breaths per minute between the animals and during
the experiment. Steady-state is reached after at least
20 min depending on the desired decrease in breathing
frequency.
Under PSA a median duty cycle of 79.5 % (IQR 72.5–
84.5, range 18.0–96.0) was achieved, while under GA
this was only 64.0 % (IQR 62.0–66.5, range 46.0–73.0).
These values differed significantly (p < 0.001).
Figure 3 shows the displacement of the diaphragm
under PSA and under GA. In the resting phase, the dis-
placement was limited to three millimeters for both
anesthesia protocols.
The duration per sonication was recorded (n = 57 for
PSA, n = 61 for GA). P-P plots showed a normal distri-
bution for the PSA group and the GA group. A Student’s
t test showed that the duration of the sonications per-
formed under PSA was significantly shorter (p = 0.000)
with mean values of 15.0 s (range 6.70–25.70 s) for PSA
and 20.3 s (range 10.0–27.0 s) for GA. This is in agree-
ment with the difference in duty cycle found between
both groups.
Monitoring of vital functions
The percentage of CO2 (end-tidal: ETCO2) in the ex-
pired air remained below 5.5 % during the entire experi-
ment performed under sedation in all five pigs. Blood
pressure and heart rate values remained within the nor-
mal range during all sonications under PSA in all pigs.
Apnea was observed in one pig while the correct dos-
ages for remifentanil and propofol were set by the veter-
inarian and biotechnicians to obtain a stable state of
sedation and respiration. Respiration was quickly re-
stored by lowering the dosage of remifentanil and by in-
ducing several inhalations manually with a self-inflating
bag. Under GA, all vital functions were stable and within
the standard range. No abnormalities were observed.
Fig. 3 Displacement of the diaphragm as measured with MRI. Top: general anesthesia (GA). Bottom: procedural sedation and analgesia (PSA). The
displacement of the diaphragm is in both cases less than 3 mm during the resting phase causing only a small heat-spread during ablation. The resting
phase is longer under PSA, which is due to the dosages of remifentanil and propofol and the settings of the mechanical ventilator used under GA
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Patient treatments
During all three patient treatments under PSA, the
breathing cycle could be depressed to values as low as 5
per minute with a rapid inhalation and exhalation phase
and a long resting phase as visualized by capnography.
The ETCO2 level stayed below 6.5 %. Blood pressure
and heart rate values remained within the normal range
indicating the absence of pain sensation that can be
caused by HIFU. The displacement of the diaphragm
over time is shown in Fig. 4. In the presented case, the
maximum displacement is 3 cm after inhalation. A rest-
ing phase could be observed of 5–10 s between breaths,
which was found similar in all three patients. Particularly
noteworthy is the change of the diaphragm kinetics from
a smooth inhalation/exhalation event under non-
depressed free-breathing to a breathing pattern with a
short and rapid gas exchange, followed by long plateau
of immobility of the diaphragm.
Discussion
Previous work demonstrated that respiratory-gated HIFU
energy delivery and MR-guidance can achieve confluent
treatment volumes in porcine liver tissue within a clinic-
ally accepted time frame under the conditions of general
anesthesia [10]. In this study, we investigated if compar-
able results can be achieved by releasing the requirement
for general anesthesia and instead delivering acoustic en-
ergy during a partially depressed but free-breathing mo-
tion pattern, which results from a tailored procedural
sedation and analgesia protocol. PSA is known to cause
fewer complications, to provide for a faster recovery after
treatment, and to decrease the burden for the patient,
without hampering the MR-HIFU treatment.
The data of the pencil beam navigator, which tracked
the displacement of the diaphragm over time directly,
displays minimal displacement during the resting phase
of the breathing cycle under PSA. Over the duration of
5–7 s, the diaphragm was found virtually completely
static, allowing long periods of energy delivery by MR-
HIFU to the target volume without any requirement of
sophisticated motion correction. Free breathing patterns
without respiratory depression show after the initial
rapid inhalation event typically long transitional phases
between inhalation and exhalation, during which the dia-
phragm is slowly moving [43]. Moreover, typical reper-
tory motion patterns under free-breathing are only
periodical over short epochs of 20–30 s, before the pat-
tern changes or is interrupted by spontaneous motion
events. Both characteristics were entirely suppressed by
the remifentanil-propofol protocol used in this study.
The respiratory pattern has been found to be very regu-
lar and free of spontaneous breathing events over epochs
of 1 h without visible modifications to the pattern, nor a
measurable degradation of the vital functions of the ani-
mal. Furthermore, this breathing pattern was found
reproducible in all animals and little variation was ob-
served inter-individually. This is of significant clinical
value, as PSA protocols need to be reliable and reprodu-
cible for patient care.
The resulting breathing pattern with long static phases
of the diaphragm obtained under PSA with remifentanil
and propofol results in similar NPVs and non-viable vol-
umes (NADH staining) as published previously [10] and
as shown in this study acquired under GA. The lesions
ablated under PSA were confluent and created at the
intended location in the liver. These effects were repro-
ducible, since they were observed in all seven animals.
Although NADH staining is a reliable indicator of
mitochondrial activity and thus cell viability, its sensitiv-
ity is limited within the first hours after HIFU ablation,
since it takes only acute cell death into account and not
the result of apoptosis. This often results in an under-
estimation of the necrotic tissue area [55, 56] and a mis-
match with the NPV, which is typically found larger.
Since the animals were sacrificed at the end of the ex-
periments, any increase of the necrotic volume over time
could not be measured. This effect has been observed
previously for MR-HIFU of the liver [10]. Also in this
study, the mismatch between the NPV and non-viable
NADH volume has been observed, especially for the
Fig. 4 Displacement of the diaphragm in a patient under procedural sedation and analgesia measured with MRI. Resting phases of 5–10 s can
be observed
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GA ablation volumes, since these were performed
after the PSA ablations and thus sooner upon termin-
ation of the animal.
NPV volumes per sonication were higher for ablations
performed under sedation than for sonications under
GA. Also, the non-viable volumes obtained by NADH
staining of the tissue sections showed larger necrotic
volumes for PSA than for GA. These values are influ-
enced by the duty cycle and thus by the breathing fre-
quency. The breathing frequency was set to a fixed value
under GA in order to maintain comparability to previ-
ous work on MR-HIFU of the liver [10] and was lower
under PSA. Similar results for PSA and GA can be ex-
pected if the breathing frequency of the GA protocol
would have been matched to the results obtained during
PSA on an inter-individual basis. Therefore, the results
obtained under PSA have not to be considered superior
to GA, but we can conclude that essentially equivalent
results can be achieved with either method.
More important is the displacement of the diaphragm,
which is an estimate of the displacement of the liver. Large
displacements during sonications cause heat-spread. The
consequence of this effect is twofold: (1) The temperature
in the target region may not reach 56 °C resulting in dam-
age but not in complete cell death in the ablation area,
which has major consequences when treating malignant
tumors and (2). Healthy tissue might be damaged, which
is undesirable. We have shown in this study that the re-
sidual motion of the diaphragm in the resting phase of the
breathing cycle is <3 mm both under PSA and under GA.
This is very small compared to the displacement during
inhalation and exhalation, which is 20–25 mm, as is
shown in Fig. 3, and was found acceptable for accurate en-
ergy delivery as is previously shown by our group using
the same tidal volume [10].
The decrease in breathing frequency and the long
resting phase of the diaphragm are specific characteris-
tics of remifentanil usage. Remifentanil is a very potent
opioid and is metabolized by non-specific esterases to a
much less potent metabolite [57]. Apart from its de-
pressant effect on the respiratory cycle, it has other ad-
vantages. It has rapid onset of action (blood-brain
equilibration time of 1 min) [58], as well as a short
half-life time ranging between 3 and 5 min, which is in-
dependent of the duration of the infusion [49]. Remi-
fentanil allows for a rapid transition from intense
analgesia to minimal residual effect [49]. Recovery from
PSA with remifentanil is therefore very quick, which is
beneficial for clinical practice, in particular considering
elderly and/or fragile patients. Additionally, remifenta-
nil has a strong analgesic effect that can alleviate symp-
toms of discomfort caused by the treatment.
Propofol is a widely used hypnotic/amnestic drug for sed-
ation during a broad range of interventional procedures
[49, 59]. It has several advantages, such as rapid onset of
the sedative effect (approximately 30 s), a short action time
(distribution half-life 2–4 s and elimination half-life 30–
60 s), and a rapid and complete recovery profile, and it in-
duces both sedation and amnesia, which is favorable to the
patient considering the duration of MR-HIFU procedures
[60, 61]. However, propofol lacks analgesic effects and does
not induce respiratory depression. Therefore, the combin-
ation of remifentanil and propofol appears complementary.
Other advantages of this combination are the decrease in
pain arising from propofol injection by remifentanil, the de-
crease in nausea and vomiting due to opioids by propofol,
the reduced required dose of both medications when ad-
ministered together, and resulting accelerated recovery [62].
However, as we observed in this study, the induction
of a partial respiratory depression inherently introduces
the risk of respiratory arrest due to remifentanil over
dosage. Fortunately, in this case, the respiratory cycle
can be quickly restored to a stable pattern by decreasing
the dosage due to the high clearance rate, while provid-
ing mechanically assisted ventilation. When inducing
sedation with remifentanil, the starting dose should be
in the lower range of known effective dosages and the
dosages of both remifentanil and propofol should be
attuned during the preparation phase of the treatment
to find the ideal state, which is stable and induces the
desired breathing frequency. Vital functions should be
monitored closely during this phase and should stay
within the standard range (ETCO2: 36 ± 5 mmHg or ±
5 % [63–65]). Nevertheless, the dosages administered
during all three MR-HIFU procedures in patients were
comparable to the values of clinically established sed-
ation protocols for, e.g., endoscopy procedures under
remifentanil and propofol (0.05 μg/kg body weight/min
remifentanil and 50 μg/kg body weight/min propofol
[49]) and are thus in their added risks and the required
emergency procedures well understood.
On the other hand, the supporting veterinary depart-
ment did not have an established protocol for PSA with
remifentanil and propofol for treatments requiring par-
tial respiratory depression in a porcine model. Therefore,
the exact protocol, in particular the dose escalation of
each drug had to be developed in the scope of this study
in the preparation of each treatment. In particular, in the
initial phase of the study (n = 1, 2), this did lead to a pro-
longed preparation until the animals reached a stable
breathing pattern. For later experiments (n = 3–8), the
duration between the induction of PSA until a stable
breathing pattern was reached required ~20 min. In
comparison, dosages used for GA during the porcine ex-
periments are well known and also the settings of the
mechanical ventilator at 13 breaths per minute with a
volume of 0.4 L per breath have been used many times
before during porcine MR-HIFU experiments [10].
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Conclusions
In the first part of this study, we demonstrated the feasi-
bility and reproducibility of MR-HIFU ablations of the
liver under remifentanil and propofol induced PSA in a
porcine model. We have shown that partial respiratory
depression resulting in a long resting phase of the dia-
phragm and high duty cycles of acoustic energy delivery
is feasible. The clinical application of this sedation
protocol would be MR-HIFU treatments of small pri-
mary or metastatic liver tumors in human patients.
Therefore, we explored in the second part of this study
in three patients treated with MR-HIFU (uterine fibroid
and a bone metastasis) if the main findings, in particular
the possibility to reduce the breathing frequency to 5/
min, while obtaining a long exhalation period in which
the diaphragm is stationary, are transferable from the
porcine model to patients. We confirmed the low
breathing frequency and high duty cycle desired for suc-
cessful MR-HIFU treatments in three patients using the
same combination of medication and while maintaining
stable vital functions. Furthermore, we showed that a
resting phase of the diaphragm of 5–10 s could be in-
duced under PSA in one patient. In conclusion, we
propose the combination of remifentanil and propofol
during MR-HIFU as PSA is less invasive and carries
fewer risks for the patients while showing equal results
when compared to GA.
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